Walgreens cuts profit view, to shut more stores on spending hit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
TD Cowen on Walgreens Boosts Alliance (WBA): 'continued challenges in retail pharmacy'
June 27, 2024 8:51 AM EDTTD Cowen analyst Charles Rhyee reiterated a Buy rating and $35.00 price target on Walgreens Boosts Alliance (NASDAQ: WBA).
The analyst comments "F3Q adj EPS $0.63 missed cons $0.69. WBA narrowed FY24 guide to $2.80-$2.95 (from $3.20-$3.35), which assumes continued challenges in retail pharmacy.... More
RBC Capital on Walgreens (WBA): 'ongoing consumer weakness and pressure on pharmacy margin'
June 27, 2024 8:28 AM EDTRBC Capital analyst Anton Hie reiterated a Sector Perform rating and $22.00 price target on Walgreens Boosts Alliance (NASDAQ: WBA).
The analyst comments "WBA posted fiscal 3Q24 earnings slightly below expectations driven by ongoing consumer weakness and pressure on pharmacy margin, partially offset by another quarter of good International performance and positive EBITDA contribution from U.S. Healthcare. Management lowered its adjusted EPS guidance by $0.40 at the midpoint, or -12%... More
Walgreens shares dive after guidance cut, stores closure plans
June 27, 2024 7:34 AM EDTWalgreens Boots Alliance (NASDAQ: WBA) saw its shares tumble 10% in premarket trading Thursday after the retail pharmacy chain reported worse-than-expected Q3 earnings and reduced its full-year guidance.
The company posted Q3 earnings per share (EPS) of $0.63, falling short of the consensus estimate of $0.71. Revenue came in at $36.4 billion, slightly above the estimated $36... More
